LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced it has initiated an operational, technical, and commercial evaluation process to potentially integrate installment-based healthcare payment capabilities through Cashea, a leading buy-now-pay-later financial technology platform in Venezuela. The proposed initiative aims to reduce upfront financial barriers for patients seeking private healthcare services, including consultations, diagnostics, wellness programs, and other offerings within the LataMed AI ecosystem.
Management believes that improving payment accessibility could support greater patient engagement, increased healthcare utilization, stronger platform adoption, and broader access to private healthcare services. By addressing affordability challenges, the company aims to strengthen its position as a technology-enabled healthcare marketplace serving patients, providers, and healthcare partners throughout Latin America. The potential integration with Cashea aligns with LataMed AI's broader strategy of combining artificial intelligence, telehealth infrastructure, care coordination tools, and digital payment accessibility to create a more scalable healthcare marketplace.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated, "We believe financial accessibility is a critical component of healthcare delivery. Our objective is to evaluate solutions that may help patients obtain timely medical care while simultaneously expanding the reach and utility of our healthcare ecosystem. We believe initiatives such as this have the potential to strengthen patient acquisition, improve engagement, and support long-term platform growth."
The company has not entered into a definitive commercial agreement related to this initiative as of the date of the release. Completion of any integration remains subject to further commercial discussions, technical implementation requirements, regulatory review, and customary business conditions. LataMed AI intends to provide additional updates as material developments occur.
For additional information, visit the company's website at https://latamed.ai or review its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
